Effects of carnitine and its congeners on eicosanoid discharge from rat cells: implications for release of TNFα by Garrelds, Ingrid M. et al.
Research Paper
Mediators of Inflammation 2, S57-S62 (1993)
THE acyl carrier coenzyme A (CoA) is involved in fatty
acid metabolism. The carnitine/CoA ratio is of particular
importance in regulating the transport of long-chain fatty
acids into mitochondria for oxidation. Also CoA has a role
in the formation and breakdown of products from both the
cyclooxygenase and lipoxygenase pathways of the pre-
cursor arachidonic acid. In the present study the effect of
4 days feeding of 300 mg/kg/day of L-carnitine, acetyl L-
carnitine and propionyl L-carnitine on the basal and calci-
um ionophore (A23187) stimulated release of arachidonic
acid metabolites from rat carrageenin elicited peritoneal
cells was investigated. There were two series of experi-
ments carried out. In the first, the harvested peritoneal
cell population consisted of less than 90% macrophages
and additional polymorphonuclear (PMN) leucocytes.
The basal release of prostaglandin E2 (PGE2), 6-keto-
prostaglandin FI= (6-keto-PGFl=) and leukotriene B
(LTB4) was stimulated by all treatments. The A23187
stimulated release of 6-keto-PGFla and LTB was in-
creased by all three compounds. The 6-keto-PGFla:TxB
and 6-keto-PGFla:LTB ratios were increased by carnitine
treatment. These results suggested that carnitine could
modify the macrophage component of an inflammatory
site in io. In the second series of experiments the
harvested cell population was highly purified (>95%
macrophages) and none of the compounds fed to the rats
caused a change of either eicosanoid or TNFt formation.
Moreover the 6-keto-PGFla:TxB2 and 6-keto-PGFI=:LTB
ratios were not enhanced by any of the compounds tested.
It is conceivable that in the first series the increased ratios
6-keto-PGFl=:TxB and 6-keto-PGFla:LTB reflected the
effect of carnitine or its congeners on PMN leucocytes
rather than on macrophages.
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Introduction
Fatty acids are oxidized in mitochondria. They
are activated before they enter the mitochondrial
matrix. Adenosine triphosphate (ATP) drives the
formation of a thioester linkage between the
carboxyl group of a fatty acid and sulphydryl group
of coenzyme A (CoA). This reaction occurs on the
outer mitochondrial membrane, where it is
catalysed by acyl CoA synthetase (also called fatty
acid thiokinase). The activation of a fatty acid
occurs in two steps. First, the fatty acid reacts with
ATP to form an acyl adenylate. In this mixed
anhydride, the carboxyl group of a fatty acid is
bonded to the phosphoryl group of adenosine
triphosphate (AMP). The sulphydryl group of CoA
then attacks the acyl adenylate, which is tightly
bound to the enzyme, to form acyl CoA and AMP.
Fatty acids are activated on the outer mitochon-
drial membrane, whereas they are oxidized in the
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mitochondrial matrix (Fig. 1). Long-chain acyl CoA
molecules do not readily transverse the inner
mitochondrial membrane, and so a special transport
mechanism is needed. Activated long-chain fatty
acids are carried across the inner mitochondrial
membrane by L-carnitine (fl-hydroxy-0:-N-trime-
thylammonio)-butyrate), a zwitterionic compound
formed from lysine. The acyl group is transferred
from the sulphur atom of CoA to the hydroxyl
group of carnitine to form acyl carnitine. This
reaction is catalysed by carnitine acyltransferase I,
which is located on the cytosolic face of the inner
mitochondrial membrane. Acyl carnitine is then
shuttled across the inner mitochondrial membrane
by a translocase. The acyl group is transferred back
to CoA on the matrix side of the membrane. This
reaction is catalysed by acyltransferase II.
1-3
CoA also has a role in the formation and
breakdown of products from both the cyclooxy-
genase and lipoxygenase pathways of the fatty
Mediators of Inflammation- Vol 2 (Supplement) 1993 S57L M. Garrelds et al.
Activation
in cytosol
Transport
in membrane of mitochondrial
Oxidation
in matrix
Fatty acid
+ CoA
acyl CoA
synthetase
Acyl CoA
-i- carnitine
CoA
A arnitine
Carn
Eicosanoids
itin
 Acyl CoA
Acyl carnitine
FIG. 1. Schematic representation of the activation of long-chain fatty acids in the cytosol, the entry of acyl carnitine into the mitochondrial matrix
mediated by a translocase and the oxidation of acyl CoA in eicosanoids in the mitochondrial matrix.
acid, and arachidonic acid metabolism.4 Recently
the oxidation of the cyclooxygenase product
prostaglandin E2 (PGE2) in rat liver peroxisomes
and mitochondria was shown to require the
activation to PGEe-CoA by microsomal PGE2-
CoA synthetase. PGE2 is recognized as an
important inhibitor of cell migration and of
mediator formation at inflammatory sites. En-
hanced formation of cyclic AMP is involved in
these inhibitory effects. Similar inhibitory effects
may be exerted by prostacyclin (PGI2) which also
enhances the intracellular levels of cyclic AMP. The
lipoxygenase metabolite leukotriene B4 (LTB4) is
degraded through omega- and beta-oxidation in
neutrophils and liver cells. The formation of
LTB4--CoA esters which occurs in rat liver
microsomes may be essential for LTB4 beta-
oxidation.
6 LTB4 is a potent chemotactic agent and
promotes the formation of mediators at inflam-
matory sites. The degradation products of LTB4
are less potent than the parent compound. Hence
the formation of LTB4-CoA esters and their
subsequent beta-oxidation might be of importance
in limiting LTB4 activity at the sites of inflamma-
tion. Macrophages secrete a large variety of
cytokines, such as interleukines and tumour
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necrosis factor z (TNFz). In normal human alveolar
macrophages, when stimulated for 24h with
lipopolysaccharide (LPS), the cyclooxygenase path-
way was stimulated specifically.
7 A high PGE2
concentration inhibits TNF by increased levels of
cyclic AMP. A low PGE2 augments a high TNF
production, which is stimulated by guanylate
cyclase. 8’9 Carnitine is known to enhance the
formation of arachidonic acid from linoleic acid by
isolated hepatocytes, since long-chain acyl carnitine
can remove the inhibitory effect of long-chain acyl
CoA on acetyl CoA carboxylase, a regulating
enzyme in the fatty acid synthesis.
1 The serum
carnitine and leucine levels were significantly
decreased in patients on continuous ambulatory
peritoneal dialysis (CAPD) for more than 4 months
compared with levels of controls. This data
suggested that malnutrition plays a role in the
decrease of serum carnitine levels in patients
receiving CAPD.
11 L-Carnitine has several beneficial
effects on ischaemic heart diseases and arrhythmias
in humans, where the drug augments the ischaemic
heart tolerance to stress.
12 Camitine deficiency can
be defined as a decrease of intracellular camitine,
leading to an accumulation of acyl CoA esters and
an inhibition of acyl transport via the mitochondrialEffect of carnitine on eicosanoid discharge
inner membrane. Inhibition of the mitochondrial
oxidation of long-chain fatty acids during fasting
causes heart or liver failure. Patients with
cardiomyopathy due to carnitine loss are improved
by carnitine supplementation.
13-15
In the present study on the role of carnitine in
the eicosanoid and cytokine production at inflam-
matory sites, the eicosanoids formed from basal
and A23187 stimulated, and TNF formed from
basal and LPS stimulated carrageenin induced
peritoneal ceils of rats after feeding L-carnitine,
acetyl I-carnitine (formed during /-oxidation of
even-chain fatty acids) and propionyl I-carnitine
(formed during /-oxidation of uneven-chain fatty
acids) were determined.
Materials and Methods
Animals and treatment: Male Wistar rats were given
300 mg/kg carnitine or carnitine equivalent (acetyl
carnitine and propionyl carnitine) (gifts of Sigma-
Tau, Italy) dissolved in 1 ml distilled water, by
intubation on days 1-4. Control animals were given
distilled water. All animals were injected with 2 ml
of a carrageenin (Marine Colloids Inc., USA)
solution (1 mg/ml) intraperitoneally on day 1.
Isolation/incubation of peritoneal cells: Two series of
experiments were carried out. In the first series
(with neutrophil contamination > 10%) on day 4,
1 h after the last administration of carnitine(s), the
cells were isolated from pooled Gey’s balanced salt
solution washes of the peritonea of the rats (four
rats/group) by density gradient centrifugation over
Lymphoprep (Nyegaard Diagnostica, Norway) and
suspended in Dulbecco’s modification of Eagle’s
medium (DMEM) (2 x 106 nucleated cells). The
harvested peritoneal cell population consisted of
less than 90% macrophages and >10% PMN
leucocytes. Portions (1 ml) of suspension were
incubated at 37C for either 2 h (basal release) or
30 min with 10
-6 M A23187 (ionophore stimulated
release). The cells were then centrifugated and the
supernatant fractions analysed for production of
leukotriene 84 (LTB4) prostaglandin E2 (PGE2),
thromboxane Be (TxB2) and 6-keto-prostaglandin
FI (6-keto-PGFl) by radioimmunoassays. 16’17
In the second series of experiments (without
neutrophil contamination) on day 4, 1 h after the
last administration of carnitine(s), the cells were
obtained from each separate rat (nine rats/group)
by washing the peritoneal cavity with 2 x 20 ml of
phosphate buffered saline (PBS) (Oxoid, UK). The
macrophages were isolated by density gradient
centrifugation with Lymphoprep (Nycomed, Nor-
way) and suspended in Dulbecco’s modification of
Eagle’s medium (DMEM) (Life Technologies Ltd,
UK) (2 x 106 macrophages/ml). The harvested cell
population consisted of > 95% macrophages,
approximately 3% PMN leucocytes and 2% other
cells (lymphocytes, erythrocytes). Portions (1 ml) of
suspension were incubated at 37C for 30 min with
or without 10-6M A23187 (Sigma, USA) (iono-
phore stimulated release) and 24h with or
without 5/g/ml LPS. The cells were then
centrifugated and the supernatant fractions analysed
for production of LTB4, PGE2, TxB2 and 6-keto-
PGF, by radioimmunoassays (basal and A23187
stimulated), and TNF0 by MTT-tetrazolium
bioassay (24 h with or without LPS). 17’18
Statistical analysis: In the first series of experiments
the values are given as the mean for each point
SEM of three experiments. In the second series,
the results are expressed as the mean _--F SEM of
nine experiments. Statistical significance was
calculated using the two-tailed Mann-Whitney U
test.
Results
Effect offeeding of carnitine or its congeners on the number of
carrageenin inducedperitoneal cells: In the first series (with
neutrophil contamination) of experiments all three
compounds significantly reduced, by about half, the
number of nucleated cells isolated from peritonea
4 d after an intraperitoneal injection of carrageenin
(x 106 -+_ SEM per rat)" control 13 -F 2, carnitine
6-F 1; acetyl carnitine 5 1, propionyl carnitine
6 + 0.6.16
In the second series (without neutrophil
contamination) of experiments none of" the
compounds fed to the rats caused a decrease in
the number of" macrophages accumulated in the
peritoneal cavity (x 106+ SEM per rat)" control,
3.6-}-0.5, carnitine, 4.4 _+0.6, acetyl carnitine,
3.3 _+ 0.4, propionyl camitine, 4.6 _+ 0.4.
Effect offeeding of carnitine or its congeners on the basal and
A23187 stimulated release of eicosanoids from carrageenin
induced peritoneal cells: In the first series (with
neutrophil contamination) of experiments the basal
release of PGE2, 6-keto-PGF and LTB4 was
stimulated by all treatments. In contrast, TxB2
production was inhibited by feeding carnitine and
acetyl carnitine or not modified by feeding
propionyl carnitine (Fig. 2, Table 1). A23187
stimulated synthesis of 6-keto-PGFl= and LTB4 was
further enhanced by all three compounds and acetyl
carnitine and propionyl carnitine treatments in-
creased the formation of TxB2. However, no effects
on PGE2 formation were detected (Fig. 3, Table 1).
The 6-keto-PGF=’TxB2 ratio, calculated from the
basal and A23187 stimulated values, was increased
by carnitine treatment (Table 2). In the presence of
A23187 there was also an increase in the
6-keto-PGF=’ LTB4 ratio (Table 2).
16 In the second
Mediators of Inflammation. Vol 2 (Supplement). 1993 S59I. M. Garrelds et al.
Control Carnitine Ac carnitine Pr carnitine
I=
._=
o
x
Control Carnitine Ac carnitine Pr carnitine
FIG. 2. Effect of feeding of carnitine or its congeners on the basal release
of prostaglandin E ([]), thromboxane B (1) and 6-keto-prostaglandin
FI= (II) from carrageenin induced peritoneal cells with or without
neutrophil contamination. Statistical significance to the control group is
shown as *p < 0.05 according to Mann-Whitney U test.
Control Carnitine Accarnitine Prcarnitine
Contro Carnitine Ac carnitine Pr carnitine
FIG. 3. Effect of feeding of carnitine or its congeners on the A23187
stimulated release of prostaglandin 52 ([]), thromboxane B () and
6-keto-prostaglandin FI= ([]) from carrageenin induced peritoneal cells
with or without neutrophil contamination. Statistical significance to the
control group is shown as *p < 0.05 according to Mann-Whitney Utest.
series (without neutrophil contamination) of
experiments the basal and the A23187 stimulated
release of PGE2, TxB2, 6-keto-PGFl= and LTB4
were not increased (Figs 2 and 3, Table 1).
The 6-keto-PGFl:TxB2 and the 6-keto-
PGF:LTB4 ratios were not enhanced by any of
the compounds tested (Table 2).
Discussion
It was recently shown that in a peritoneal cell
population obtained from patients with ascites
consisting of 77% macrophages, 16% PMN
leucocytes and 7% other cells (lymphocytes,
eosinophils) a marked production of 6-keto-PGFl=
and 12-hydroxy-5,8,10-heptadecatrienoic acid
(HHT) took place, whereas hardly any metabolites
of the cyclooxygenase pathway, but mainly
products of lipoxygenase, such as LTB4 and
5-hydroxy-eicosatetraenoic acid (5-HETE) were
observable with a highly purified peritoneal
macrophage population (Fig. 4). 19’20 It is thus
conceivable that the increased 6-keto-PGFl:TxB2
and 6-keto-PGFI:LTB4 ratios in the first series of
experiments reflected the effect of carnitine and/or
its congeners on PMN leucocytes rather than on
macrophages.
L-carnitine was shown in vitro to exert an
inhibitory influence on chemiluminescence in
phorbol-myristate-acetate stimulated human PMN
leucocytes.
12 Chemiluminescence is under the
inhibitory control of those prostaglandins which
exert their effect through enhanced levels of cyclic
AMP via activation of the adenylate cyclase
Table 1. Effect of feeding of carnitine or its congeners on the basal and A23187 stimulated
release of LTB4 (ng/2 x 106 macrophages)from peritoneal cells. Values are means __+ SEM
Treatment Control Carnitine Acetyl carnitine Propionyl carnitine
Neutrophil contamination
Basal 0.07 + 0.01 0.10 + 0.03* 0.14 + 0.06* 0.12 + 0.04*
+A23187 0.84 + 0.24 1.64 + 0.38* 1.86 + 0.32* 1.31 + 0.31
Without neutrophil contamination
Basal 0.41 + 0.06 0.36 + 0.04 0.30 _+ 0.03 0.30 + 0.03
+A23187 3.77 _+ 1.11 1.86 __+ 0.30 3.49 _+ 1.12 2.67 -t-0.59
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Table 2. Effect of feeding of carnitine or its congeners on the 6-keto-PGFl=:TxB2and 6-keto-
PGFI=:LTB4 ratios of the basal and A23187 stimulated release of the eicosanoids from peritoneal cells.
Values are means -I- SEM
Treatment Control Carnitine Acetyl carnitine Propionyl carnitine
Neutrophil contamination
6kPGFI=:TxB2
Basal 0.22 + 0.01 0.86 + 0.12* 1.57 :t- 0.22* 1.00 + 0.36*
+A23187 1.02 _+ 0.21 4.95 _+ 2.33* 1.36 + 0.23 0.82 ___
0.15
6kPGFI=’LTB4
Basal 21.35 + 2.29 24.70 7.21 45.40 + 25.43 24.40 _+ 6.09
+A23187 6.70 + 1.65 15.19 _+ 4.10" 10.78 + 2.93 9.1’4 ___
2.22
Without neutrophil contamination
6kPGF=:TxB2
Basal 0.48 + 0.06 0.31 + 0.03* 0.38 + 0.06 0.62 _+ 0.09
+A23187 0.90 + 0.23 0.22 + 0.04* 0.42 + 0.13 0.33 + 0.04*
6kPGF" LTB4
Basal 8.47 _+ 1.14 5.76 _+ 0.56 7.62 +__ 0.96 11.41 +_ 1.82
+A23187 6.03 _+ 1.42 2.18 _+ 0.44* 4.06 _+ 0.86 3.38 ___
0.61
complex. Macrophages obtained from renal patients
on continuous ambulatory peritoneal dialysis
(CAPD) during an episode of infectious dialysis
show a decrease in cyclic AMP and PGE2
production and an increase inTNF and interleukin
1/ (IL-1/g). a cyclic nucleotide mediated influence
of PGE2 is recognized in the regulation of the
production of TNF0 from macrophages.21’22 TNF
3O
0 "
15
75
O 50
25
O
.1::
0
FIG. 4. Arachidonic acid metabolites formed by peritoneal cells of patients
with ascites, expressed as the mean percentage of total formation of the
most common metabolites ___
SEM with or without neutrophil con-
tamination.
synthesis in peritoneal rat macrophages is up-
regulated by cGMP and down-regulated by cAMP,
which indicates that cyclic nucleotides act as
intracellular messengers for extracellular signals of
macrophage activation. Whether increased produc-
tion of prostaglandins and subsequently elevated
levels of cyclic AMP are involved in the effect of
L-carnitine on PMN leucocytes still needs to be
examined. Enhanced production of prostaglandins
in PMN leucocytes might have, via an interaction
with concomitantly present macrophages, implica-
tions for a conceivable influence of L-carnitine or
its congeners on the release of TNF. However we
were unable to observe that TNF formation was
significantly influenced by carnitine and its
congeners both in rested and stimulated macro-
phages (data not shown). From these negative
findings one could conclude that (i) the treatment
regime was inappropriate to influence the release of
mediators of inflammation; (ii) in this type of
inflammation a clear interrelationship between
PGE2 and TNF does not exist; and (iii) the in vitro
effects of carnitine and its congeners on macro-
phages are not representative for the in vivo
situation, in which the involvement ofpolymorpho-
nuclear cells and their production of prostaglandins
might be of importance for the discharge ofTNF
from macrophages.
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